Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839279 · ClinicalTrials.gov registry record · Phase 2
A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
A Phase 2 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT01839279 is a Phase 2 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 136 participants.
The verdict
NCT01839279, a Phase 2 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Tizanidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839279
The ClinicalTrials.gov registry entry for NCT01839279 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01839279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839279 about?
NCT01839279 is a clinical study titled "A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial". This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit...
What is the current status of trial NCT01839279?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2013-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01839279?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Tizanidine (DRUG).
Who is sponsoring clinical trial NCT01839279?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.